Abstract
Effective agents with a favorable toxicity profile are needed for women with advanced ovarian cancer. PEGylated liposomal doxorubicin (PLD) is safe and effective as monotherapy for advanced ovarian cancer. It was compared with topotecan in a large Phase III trial in this patient population and was found to be associated with less severe adverse events. In platinum-sensitive patients, PLD was associated with a statistically significant survival advantage over topotecan. PLD is currently under further investigation to expand its role in the treatment of ovarian cancer into combination regimens with carboplatin as first-line treatment, as maintenance therapy as a single-agent, and in combination with molecularly targeted agents in the salvage setting.
Financial & competing interests disclosure
Stephen Welch is a clinical fellow in the New Drug Development Program at Princess Margaret Hospital. Amit Oza has been an investigator on clinical trials sponsored by Schering-Plough Pharmaceuticals and is a paid consultant for Schering-Plough. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.